Investors Relations

Evax AG is a swiss biotech company focusing on equine health. We combine cutting-edge technologies and bring the latest efforts from human medicine into horses at an affordable price. Evax AG has a unique portfolio of innovative therapeutic candidates with a compelling underlying biology in areas of unmet needs in equine medicine.

Currently we accelerate commercialization of our lead candidate therapeutic vaccine, which will be entering GMP manufacturing and pivotal trials.

For Investor Relations related information or questions, please contact:

Antonia Gabriel, CEO
Mail: antonia@evax.ch

Daniel Widmer, COO
Mail: daniel@evax.ch

Pipeline